Axonics (NASDAQ:AXNX) quickly rose 1% after Boston Scientific (BSX) said it will no longer offer Coaptite as of Nov. 1. Investors believe the announcement may mean that Boston Scientific (BSX) agreed ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
Former FierceMedTech Fierce 15 winner Axonics Modulation Technologies has received FDA approval for its rechargeable neuromodulation implant to treat bowel dysfunction. According to the company, its r ...
Axonics Modulation Technologies has released topline clinical results from its ARTISAN-sacral neuromodulation (SNM) pivotal study. The Irvine, CA-based company’s Axonics r-SNM System was evaluated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results